CHICAGO, IL / ACCESS Newswire / April 30, 2026 / Cosmos Health Inc. (&#34;Cosmos Health&#34; or the &#34;Company&#34;) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it is projecting

<p><strong id="dateline">CHICAGO, IL / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 30, 2026 / </strong><a rel="nofollow" href="https://pr.report/l6ul"><strong>Cosmos Health Inc.</strong></a><strong> ("Cosmos Health" or the "Company")</strong><a rel="nofollow" href="https://pr.report/5zI9BhPZ"><strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>)</strong></a>, a diversified, vertically integrated global healthcare group, today announced that it is projecting Cur18<sup>&#8482;</sup> to generate over $2.5 million in incremental annual revenue in the United States within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions.</p><p>Cur18<sup>&#8482;</sup> is part of the Company's recently introduced "18 Series," a portfolio of science-based nutraceutical products. It is a curcumin-based dietary supplement formulated with a proprietary ingredient that has been evaluated in published pharmacokinetic and clinical studies and is positioned within the U.S. turmeric/curcumin supplement category.</p><p>The Company's projection reflects a phased market entry strategy, initially focused on direct-to-consumer e-commerce channels, with potential expansion into selected retail channels over time. It is based on internal assumptions regarding pricing, expected sales volumes, and the gradual expansion of distribution, and is subject to the continued execution of the Company's commercialization strategy.</p><p><strong>Greg Siokas, Chief Executive Officer of Cosmos Health, stated: </strong>"Cur18<sup>&#8482;</sup> represents an important step in the commercialization of our 18 Series in the United States. Our focus is disciplined execution - entering a large and established category with a clearly positioned, science-supported product. The projected revenue reflects our current expectations based on our commercialization plans, and we believe Cur18<sup>&#8482;</sup> has the potential to become a meaningful contributor to our broader nutraceutical portfolio as we scale distribution."</p><p><strong>About Cosmos Health Inc.</strong></p><p>Cosmos Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life<sup>&#174;</sup>, Mediterranation<sup>&#174;</sup>, bio-bebe<sup>&#174;</sup>, C-Sept<sup>&#174;</sup> and C-Scrub<sup>&#174;</sup>. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at <a rel="nofollow" href="https://pr.report/l6um">www.cosmoshealthinc.com</a>, <a rel="nofollow" href="https://pr.report/l6un">www.skypremiumlife.com</a>, <a rel="nofollow" href="https://pr.report/l6uo">www.cana.gr</a>, <a rel="nofollow" href="https://pr.report/l6up">www.zipdoctor.co</a>, <a rel="nofollow" href="https://pr.report/l6uq">www.cloudscreen.gr</a>, as well as <a rel="nofollow" href="https://pr.report/l6ur">LinkedIn</a> and <a rel="nofollow" href="https://pr.report/l6us">X</a>.</p><p><strong>Forward-Looking Statements</strong></p><p>With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (<a rel="nofollow" href="https://pr.report/l6ut">www.sec.gov</a>). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.</p><p><strong>Investor Relations Contact:</strong></p><p>BDG Communications<br/><a rel="nofollow" href="mailto:cosm@bdgcommunications.com">cosm@bdgcommunications.com</a></p><p><strong>SOURCE</strong>: Cosmos Health Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cosmos-health-projects-over-2.5-million-in-incremental-annual-revenue-1162888'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1162888" width="0" height="0"/>

COSM

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months

COSM Projects Over $2.5 Million in Annual Revenue from Cur18™

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>CHICAGO, IL / ACCESS Newswire / April 30, 2026 / Cosmos Health Inc. (&amp;#34;Cosmos Health&amp;#34; or the &amp;#34;Company&amp;#34;) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it is projecting</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Cosmos Health Inc. (NASD: COSM) projects that its Cur18™ product could bring in over $2.5 million in annual revenue within the next 12 to 18 months. This projection is based on its e-commerce commercialization strategy, emphasizing strong growth in the nutraceutical market.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>COSM projects Cur18™ to generate over $2.5M in revenue.</li><li>Cur18™ is part of the new 18 Series of nutraceuticals.</li><li>Initial market entry focuses on e-commerce distribution strategy.</li><li>Revenue projections depend on execution of commercialization strategy.</li><li>Long-term growth potential exists in targeted health markets.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Cana Laboratories S.A. (N/A)</strong>: A subsidiary manufacturing under EU standards, enhancing product credibility.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under &#039;Corporate Developments&#039; as it highlights a new product&#039;s potential impact on revenue and the company&#039;s strategic market plans. The focus on nutraceuticals positions COSM in a lucrative and expanding market segment.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Cur18™ launch could significantly boost COSM&#039;s revenue forecast.</li><li>Initial focus on e-commerce may enhance brand visibility.</li><li>Execution risks in the commercialization strategy could affect growth.</li><li>Long-term retail expansion could lead to a sustained revenue stream.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Cur18™ projected to yield over $2.5 million in revenue.</li><li>Projection timeline is 12 to 18 months.</li><li>Part of the newly introduced 18 Series of products.</li><li>Focus on direct-to-consumer e-commerce channels initially.</li><li>Company involved in pharmaceuticals, food supplements, and telehealth.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should consider a bullish position on COSM for potential revenue growth in the next year.</p>
  </section>
</section>


<p><strong id="dateline">CHICAGO, IL / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 30, 2026 / </strong><a rel="nofollow" href="https://pr.report/l6ul"><strong>Cosmos Health Inc.</strong></a><strong> ("Cosmos Health" or the "Company")</strong><a rel="nofollow" href="https://pr.report/5zI9BhPZ"><strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>)</strong></a>, a diversified, vertically integrated global healthcare group, today announced that it is projecting Cur18<sup>&#8482;</sup> to generate over $2.5 million in incremental annual revenue in the United States within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions.</p><p>Cur18<sup>&#8482;</sup> is part of the Company's recently introduced "18 Series," a portfolio of science-based nutraceutical products. It is a curcumin-based dietary supplement formulated with a proprietary ingredient that has been evaluated in published pharmacokinetic and clinical studies and is positioned within the U.S. turmeric/curcumin supplement category.</p><p>The Company's projection reflects a phased market entry strategy, initially focused on direct-to-consumer e-commerce channels, with potential expansion into selected retail channels over time. It is based on internal assumptions regarding pricing, expected sales volumes, and the gradual expansion of distribution, and is subject to the continued execution of the Company's commercialization strategy.</p><p><strong>Greg Siokas, Chief Executive Officer of Cosmos Health, stated: </strong>"Cur18<sup>&#8482;</sup> represents an important step in the commercialization of our 18 Series in the United States. Our focus is disciplined execution - entering a large and established category with a clearly positioned, science-supported product. The projected revenue reflects our current expectations based on our commercialization plans, and we believe Cur18<sup>&#8482;</sup> has the potential to become a meaningful contributor to our broader nutraceutical portfolio as we scale distribution."</p><p><strong>About Cosmos Health Inc.</strong></p><p>Cosmos Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life<sup>&#174;</sup>, Mediterranation<sup>&#174;</sup>, bio-bebe<sup>&#174;</sup>, C-Sept<sup>&#174;</sup> and C-Scrub<sup>&#174;</sup>. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at <a rel="nofollow" href="https://pr.report/l6um">www.cosmoshealthinc.com</a>, <a rel="nofollow" href="https://pr.report/l6un">www.skypremiumlife.com</a>, <a rel="nofollow" href="https://pr.report/l6uo">www.cana.gr</a>, <a rel="nofollow" href="https://pr.report/l6up">www.zipdoctor.co</a>, <a rel="nofollow" href="https://pr.report/l6uq">www.cloudscreen.gr</a>, as well as <a rel="nofollow" href="https://pr.report/l6ur">LinkedIn</a> and <a rel="nofollow" href="https://pr.report/l6us">X</a>.</p><p><strong>Forward-Looking Statements</strong></p><p>With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (<a rel="nofollow" href="https://pr.report/l6ut">www.sec.gov</a>). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.</p><p><strong>Investor Relations Contact:</strong></p><p>BDG Communications<br/><a rel="nofollow" href="mailto:cosm@bdgcommunications.com">cosm@bdgcommunications.com</a></p><p><strong>SOURCE</strong>: Cosmos Health Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cosmos-health-projects-over-2.5-million-in-incremental-annual-revenue-1162888'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1162888" width="0" height="0"/>

Cosmos Health Inc. (NASD: COSM) projects that its Cur18™ product could bring in over $2.5 million in annual revenue within the next 12 to 18 months. This projection is based on its e-commerce commercialization strategy, emphasizing strong growth in the nutraceutical market.

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News